Lates News

In the early trading on Monday, the stock price of Amgen rose by 0.9%. Prior to this, the company reported that the VESALIUS-CV study showed that its drug Repatha reduced the risk of first major cardiovascular events by 25% in high-risk patients with no prior events, and reduced the risk of first heart attack by 36%. This supports the broader use of PCSK9 inhibitors.